Psychedelics Encyclopedia

Product Information

Strumila, R.; Nobile, B.; Korsakova, L.; Lengvenyte, A.; Olie, E.; Lopez-Castroman, J.; Guillaume, S.; Courtet, P. Psilocybin, a naturally occurring indoleamine compound, could be useful to prevent suicidal behaviors. Pharmaceuticals 2021, 14, 1213. Tryptamine, along with other trace amines, is found in the central nervous system of mammals. It is hypothesized to play a role as a neuromodulator on classical monoamine neurotransmitters, such as dopamine, serotonin, norepinephrine and epinephrine. Tryptamine acts as a non-selective serotonin receptor agonist to activate serotonin receptors, and a serotonin–norepinephrine–dopamine releasing agent (SNDRA) to release more monoamine neurotransmitter, with a preference for evoking serotonin and dopamine release over norepinephrine (epinephrine) release. [77] [78] [79] Psychedelic tryptamines found in nature include psilocin, DMT, 5-MeO-DMT, and tryptamines that have been synthesized in the laboratory include 4-HO-MET, [80] 4-HO-MiPT, [48] and 5-MeO-DALT. [81] Mescaline Phenethylamines [ edit ]

Ludwig, A.M. (1968). The hypnodelic state. In Psi and Altered States of Consciousness: Proceedings of an International Conference on Hypnosis, Drugs, Dreams, and Psi, ed. by R. Cavanna & M. Ullman, 68-87. New York: Parapsychology Foundation. Osis, K. (1961). A pharmacological approach to parapsychological experimentation. In Psi and Altered States of Consciousness: Proceedings of an International Conference on Hypnosis, Drugs, Dreams, and Psi, ed. by R. Cavanna & M. Ullman, 74-75. New York: Parapsychology Foundation. Barker, S.A.; McIlhenny, E.H.; Strassman, R. A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955–2010. Drug Test. Anal. 2012, 4, 617–635. Koblan, K.S.; Kent, J.; Hopkins, S.C.; Krystal, J.H.; Cheng, H.; Goldman, R.; Loebel, A. A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia. N. Engl. J. Med. 2020, 382, 1497–1506. Giesler, P. (1984). Parapsychological anthropology: I. Multi-method approaches to the study of psi in the field setting. Journal of the American Society for Psychical Research 78, 287-328.a b c Aghajanian, G (August 1999). "Serotonin and Hallucinogens". Neuropsychopharmacology. 21 (2): 16S–23S. doi: 10.1016/S0893-133X(98)00135-3. PMID 10432484. González-Maeso, J.; Sealfon, S.C. Psychedelics and schizophrenia. Trends Neurosci. 2009, 32, 225–232. Awad, A.G.; Voruganti, L.N.P. New antipsychotics, compliance, quality of life, and subjective tolerability—Are patients better off? Can. J. Psychiatr. 2004, 49, 297–302. a b c d Timmermann, Christopher; Roseman, Leor; Williams, Luke; Erritzoe, David; Martial, Charlotte; Cassol, Héléna; Laureys, Steven; Nutt, David; Carhart-Harris, Robin (2018). "DMT Models the Near-Death Experience". Frontiers in Psychology. 9: 1424. doi: 10.3389/fpsyg.2018.01424. PMC 6107838. PMID 30174629.

Millay, J. (2001). The influence of psychedelics on remote viewing. Bulletin of the Multidisciplinary Association for Psychedelic Studies 11/1, 43-4. a b R. R. Griffiths; W. A. Richards; U. McCann; R. Jesse (7 July 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi: 10.1007/s00213-006-0457-5. PMID 16826400. S2CID 7845214. Pablos, F. de. (2002). Enhancement of precognitive dreaming by cholinesterase inhibition: A pilot study. Journal of the Society for Psychical Research 66, 88-105. Considering aspects of timing, several authors have offered advice, though no formal studies have been conducted. Both Ryzl 74 and Grof 75 suggested that the optimum period for testing psi with LSD was towards the end of the session, when the effects were levelling off – as in the Masters and Houston 76 experiments. However Pahnke 77 disagreed. As regards to the duration of the psi-task, in preference to the extended test periods favoured by some researchers, 78 Osis 79 suggested twenty minutes as the maximum for optimum performance.Despite the contrary perception of much of the public, psychedelic drugs are not addictive and are physiologically safe. [20] [21] [10] As of 2016, there have been no known deaths due to overdose of LSD, psilocybin, or mescaline. [10]